Deep Remission in Crohn ’s Disease: Optional or Quintessential

We read with great interest the recently published article by Laharie et  al,1 reporting the long-term follow-up data of patients with Crohn’s disease (CD) from the TAILORIX trial, having sustained corticosteroid-free remission on infliximab. The authors reported that around 47% of the patients had sustained corticosteroid-free clinical remission at the time of inclus ion. There was no difference concerning anal surgery, major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment between patients who achieved remission and those who did not.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letters to the Editor Source Type: research